Dr. Sarah Hartz is Assistant Professor of Psychiatry at Washington University in St. Louis, MO. Dr. Hartz holds a PhD in Statistics from the University of Illinois Urbana-Champaign (2003), and she performed her residency in Psychiatry at the University of Iowa Hospitals and Clinics and Washington University/Barnes-Jewish Hospital (2005-2009). Dr. Hartz is currently a physician scientist who has combined her background in statistics and genetics with her psychiatric training to better understand the genetics of substance dependence. Dr. Hartz's current research interests include 1) genetics of comorbidity between substance use disorders and other severe mental illness, 2) return of genetic results to research participants, and 3) application of quantitative methodologies to addiction genetics.
Recent Publications
- Goswami, S, Hartz, SM, Oliver, A, Jackson, S, Ogungbenle, T, Evans, A, Linnenbringer, E, Moulder, KL, Morris, JC, Mozersky, J et al.. Research Participant Interest in Learning Results of Biomarker Tests for Alzheimer Disease. JAMA Netw Open 2025; 8 (5): e252919. PubMed PMID:40327345 PubMed Central PMC12056564.
- Wang, G, Li, Y, McDade, E, Xiong, C, Hartz, SM, Bateman, RJ, Morris, JC, Schneider, LS. Clinical Progression on CDR-SB©: Progression Free Time at Each 0.5-unit Level in Dominantly Inherited and Sporadic Alzheimer's Disease Populations. medRxiv 2025; : . PubMed PMID:40034778 PubMed Central PMC11875246.
- Hartz, SM, Schindler, SE, Streitz, ML, Moulder, KL, Mozersky, J, Wang, G, Xiong, C, Morris, JC. Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer's disease. Alzheimers Dement (N Y) 2025; 11 (1): e70033. PubMed PMID:39949872 PubMed Central PMC11822626.
- Chaloemtoem, A, Thornton, V, Chang, Y, Anokhin, AP, Belloy, ME, Bijsterbosch, J, Gordon, BA, Hartz, SM, Bierut, LJ. Hippocampal volumes in UK Biobank are associated with APOE only in older adults. Alzheimers Dement (Amst) 2024; 16 (4): e70024. PubMed PMID:39553251 PubMed Central PMC11567847.
- Thornton, V, Chang, Y, Chaloemtoem, A, Anokhin, AP, Bijsterbosch, J, Foraker, R, Hancock, DB, Johnson, EO, White, JD, Hartz, SM et al.. Alcohol, smoking, and brain structure: common or substance specific associations. medRxiv 2024; : . PubMed PMID:39399056 PubMed Central PMC11469368.
- Mintz, CM, Knox, J, Hartz, SM, Hasin, DS, Martins, SS, Kranzler, HR, Greene, E, Geng, EH, Grucza, RA, Bierut, LJ et al.. Demographic differences in the cascade of care for unhealthy alcohol use: A cross-sectional analysis of data from the 2015-2019 National Survey on Drug Use and Health. Alcohol Clin Exp Res (Hoboken) 2023; 47 (10): 1890-1903. PubMed PMID:37864538 PubMed Central PMC10590988.
- Hartz, SM, Culverhouse, RC, Mintz, CM, Ellis, MS, Kasper, ZA, Cavazos-Rehg, P, Grucza, RA, Bierut, LJ, Cicero, TJ. Association between recent overdose and chronic pain among individuals in treatment for opioid use disorder. PLoS One 2022; 17 (11): e0271379. PubMed PMID:36441691 PubMed Central PMC9704550.
- Hartz, SM, Mozersky, J, Schindler, SE, Linnenbringer, E, Wang, J, Gordon, BA, Raji, CA, Moulder, KL, West, T, Benzinger, TLS et al.. A flexible modeling approach for biomarker-based computation of absolute risk of Alzheimer's disease dementia. Alzheimers Dement 2023; 19 (4): 1452-1465. PubMed PMID:36178120 PubMed Central PMC10060442.
- Mintz, CM, Xu, KY, Presnall, NJ, Hartz, SM, Levin, FR, Scherrer, JF, Bierut, LJ, Grucza, RA. Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder. JAMA Netw Open 2022; 5 (5): e2211634. PubMed PMID:35544135 PubMed Central PMC9096599.
- Parsley, IC, Dale, AM, Fisher, SL, Mintz, CM, Hartz, SM, Evanoff, BA, Bierut, LJ. Association Between Workplace Absenteeism and Alcohol Use Disorder From the National Survey on Drug Use and Health, 2015-2019. JAMA Netw Open 2022; 5 (3): e222954. PubMed PMID:35297970 PubMed Central PMC8931561.
The Hartz Lab Website
